|Bid||1.84 x 900|
|Ask||1.97 x 9500|
|Day's Range||1.80 - 1.91|
|52 Week Range||1.50 - 4.25|
|PE Ratio (TTM)||-3.49|
|Earnings Date||May 3, 2017 - May 8, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||9.38|
WATERTOWN, Mass., June 22, 2017-- pSivida Corp., a leader in the development of sustained release drug products and technologies, has submitted a Marketing Authorization Application to the European Medicines ...
After unveiling positive data last week from a late-stage trial of its experimental, long-acting treatment for a leading cause of blindness, Watertown-based pSivida said Thursday that it has filed for approval in Europe. The 21-employee company (PSDV) said it had submitted an application to market its product, Durasert, in the European Union. It’s a major milestone for pSivida following a turbulent 2016 in which the company’s stock price fell precipitously and it got a new CEO.
NEW YORK, NY / ACCESSWIRE / June 14, 2017 / SodaStream International's founder and CEO picked up a considerable amount of shares in his own company according to an SEC filing. Traders were impressed by ...